Travere Therapeutics, Inc. (NASDAQ: TVTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.8B. The Maz Rating grades it against the other companies in its sector.
Travere Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $49.70, Travere Therapeutics, Inc. trades at 7.3x sales and 208.2x book value. Over the last twelve months it generated about $651M of revenue and a net loss of $150M. It runs a gross margin of 94.7%, an operating margin of -20.5% and a net margin of -18.7%. It shows return on equity of -186.5%, return on invested capital of -20.1% and a free cash flow yield of 2.8%. On the balance sheet: a debt-to-equity ratio of 27.28 and a current ratio of 3.00. Over the past 52 weeks the share price ranged from $22.59 to $68.73, with a beta of 1.12.
Travere Therapeutics, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 15 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.